GH Research (NASDAQ:GHRS) Trading Down 3.1%

GH Research PLC (NASDAQ:GHRS) traded down 3.1% during mid-day trading on Wednesday . The company traded as low as $10.54 and last traded at $10.65. 11,876 shares were traded during mid-day trading, a decline of 91% from the average session volume of 134,902 shares. The stock had previously closed at $10.99.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a research report on Monday, March 4th. JMP Securities decreased their target price on GH Research from $50.00 to $39.00 and set a “market outperform” rating for the company in a research report on Friday, March 1st.

GH Research Stock Up 1.8 %

The company has a 50-day moving average price of $9.66 and a 200 day moving average price of $7.83.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). Research analysts expect that GH Research PLC will post -0.96 EPS for the current year.

Institutional Trading of GH Research

A number of institutional investors have recently bought and sold shares of the company. BVF Inc. IL boosted its position in GH Research by 12.1% during the fourth quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock valued at $60,321,000 after purchasing an additional 1,125,000 shares during the last quarter. AdvisorShares Investments LLC boosted its position in GH Research by 4.3% during the fourth quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock valued at $280,000 after purchasing an additional 1,977 shares during the last quarter. Northern Trust Corp acquired a new stake in GH Research during the fourth quarter valued at $59,000. Mirae Asset Global Investments Co. Ltd. boosted its position in GH Research by 14.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock valued at $617,000 after purchasing an additional 13,579 shares during the last quarter. Finally, RTW Investments LP boosted its position in GH Research by 53.4% during the third quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock valued at $33,438,000 after purchasing an additional 1,158,172 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies to treat psychiatric and neurological disorders. The company develops 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable mebufotenin product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD.